Welcome to
Allurion’s Blog

abril 3, 2017

Allurion Repays Massachusetts Life Sciences Center

5 years ago, the Massachusetts Life Sciences Center​ awarded us an Accelerator Loan that made the R&D and clinical testing possible for us to secure private investment. The loan program has helped countless companies grow and expand in Massachusetts. Today, we announce repayment of that loan! Thank you to the Center, Senator Karen Spilka​, and Governor Charlie Baker​ for your support. We will continue to make Massachusetts proud!

marzo 6, 2017

Elipse Balloon Multi-Center Study Published

We are pleased to announce the publication of our European multi-center trial results in Endoscopy! Thank you to our European investigators and patients who participated in a groundbreaking study on the Elipse Balloon.

mayo 6, 2016

Allurion Technologies’ Elipse Intragastric Balloon Receives Prestigious SAGES Innovation Award

Allurion Technologies announced today that its flagship product, the Elipse Balloon, has received the prestigious Emerging Technology Innovation Award from the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). The Elipse Device is the world’s first procedureless™ intragastric balloon: it is placed and removed without surgery, endoscopy or anesthesia. It is the first intragastric balloon to receive this award. The Elipse System received European Union CE marking in late 2015 and is now available at leading weight loss centers in the United Kingdom, Italy and France. Plans for commercial expansion within Europe and in the Middle East are underway. For the…

febrero 28, 2015

Slow and Steady Doesn’t Win the Race: It’s a Tie

A recently published paper in Lancet Diabetes and Endocrinology challenges the widely held notion that gradual weight loss is associated with better long-term outcomes than rapid weight loss. Purcell and colleagues randomized 200 people to either a rapid (12 weeks) or gradual (36 weeks) weight loss program (Phase 1) and then followed those who lost at least 12.5% of their weight for over 3 years to assess long-term outcomes (Phase 2). They concluded the following: After nearly 3 years of follow-up, people in both groups maintained ~30% of the weight they had lost (see figure) 81% of people in the rapid…

diciembre 5, 2014

Data Presented on New Gastric Balloons for Weight Loss

Louise Gagnon recently interviewed Allurion’s Chief Scientific Officer Shantanu Gaur for her story in General Surgery News on the Elipse Balloon. The article highlights Allurion’s presentation at this year’s International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) World Congress and underscores the key differences between the Elipse Balloon and all other gastric balloons in development. Here’s an excerpt: In an interview with General Surgery News, Dr. Gaur pointed out that the Elipse has distinct advantages over other intragastric balloons. “The difference with our device, compared to other intragastric balloons, is that it does not require endoscopy or anesthesia,” Dr. Gaur said. Click…

noviembre 19, 2014

A balloon for obesity: an option between medication and surgery?

The Elipse Balloon was recently covered by Melissa Healy of the LA Times in an article entitled A balloon for obesity: an option between medication and surgery? Here is an excerpt: For many struggling with obesity, taking one of the newly approved prescription medications for weight loss (marketed as Qsymia, Belviq and Contrave) feels like climbing a mountain with a walking cane — it’s a little help, but not enough. And bariatric surgery — a permanent replumbing of the intestinal tract that is expensive and carries the risks of major surgery — feels like a bit too much help. Could a water balloon…